NEWS & RESOURCES
Estrigenix in the news
Estrigenix Therapeutics, Inc. presents at 2nd ACE Drug Discovery Summit 2024 in London
MILWAUKEE (March 21, 2024) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the ACE Drug Discovery Summit 2024 in London. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an abstract entitled, “Discovery…
Estrigenix invited to present at the Science2Startup Symposium in Boston, April 10th
MILWAUKEE (March 8, 2024) – Estrigenix Therapeutics, Inc., was selected to speak at Science2Startup symposium in Boston on April 10th. The Symposium is an invitation-only event focused on bringing academic innovations to the attention of the Boston-based venture capital ecosystem. Estrigenix was selected as one of eight teams to present,…
CSO Karyn Frick discusses “Why women are more likely to develop Alzheimer’s Disease” on Chicago radio WLS 890AM (the Big 89)
MILWAUKEE (October 25, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company is leading the way in estrogen biology. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Rob Johnson and Jane Clauss of Chicago radio “The Big 89” regarding Alzheimer’s Disease and the increased risk for…
Estrigenix Therapeutics to Attend The Menopause Society Meeting
MILWAUKEE (Sept. 22, 2023) – Estrigenix Therapeutics, Inc., is announcing Patricia Scheller, Executive Chairwoman, and Daniel Sem, VP for Business Development will attend the The Menopause Society, (formerly known at the North American Menopause Society) Annual Meeting in Philadelphia September 27 – 30, 2023. The Menopause Society is the premier…
Estrigenix welcomes new employees
Estrigenix Therapeutics welcomed two new employees this summer, Ms. Elaina Milkie and Dr. Dulanjali Thennakoon. Ms. Elaina Milkie graduated with B.S. from the University of Wisconsin-Milwaukee (UWM) in May 2023, double majoring in Psychology and Biological Sciences. Elaina worked part time with Estrigenix in spring 2023 while completing her degree…
Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC
Estrigenix Therapeutics was one of five Wisconsin-based companies awarded matching funding from the SBIR Advance Phase 1 program funded by the Wisconsin Economic Development Corporation. The SBIR Advance program provides assistance to companies in the process of completing a project in the federal Small Business Innovation Research (SBIR) program. feedback…